1176758-04-5
Chemical Structure
Otaplimastat
Synonym(s): SP-8203
- CAS No.: 1176758-04-5
- Formula:C28H34N6O5
- Molecular Weight:534.61
IUPAC Name: N-(3-(2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)propyl)-N-(4-((3-(2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)propyl)amino)butyl)acetamide
InChIKey: SJZBPVOSFYUHFV-UHFFFAOYSA-N
SMILES: CC(N(CCCN1C(NC2=C(C=CC=C2)C1=O)=O)CCCCNCCCN3C(NC4=C(C=CC=C4)C3=O)=O)=O
Biological Activity: Otaplimastat (SP-8203), a matrix metalloproteinase (MMP) inhibitor, blocks N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity in a competitive manner. Otaplimastat also exhibits anti-oxidant activity. Otaplimastat can be used for the research of brain ischemic injury[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Otaplimastat | 98.11% | Otaplimastat (SP-8203), a matrix metalloproteinase (MMP) inhibitor, blocks N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity in a competitive manner. Otaplimastat also exhibits anti-oxidant activity. Otaplimastat can be used for the research of brain ischemic injury. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Otaplimastat (Standard) | ≥98% | Otaplimastat (Standard) is the analytical standard of Otaplimastat (HY-109097). This product is intended for research and analytical applications. Otaplimastat (SP-8203), a matrix metalloproteinase (MMP) inhibitor, blocks N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity in a competitive manner. Otaplimastat also exhibits anti-oxidant activity. Otaplimastat can be used for the research of brain ischemic injury. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Noh SJ, et, al. SP-8203 shows neuroprotective effects and improves cognitive impairment in ischemic brain injury through NMDA receptor. Pharmacol Biochem Behav. 2011 Nov;100(1):73-80. [Content Brief]
- [2]. Noh SJ, et, al. SP-8203 reduces oxidative stress via SOD activity and behavioral deficit in cerebral ischemia. Pharmacol Biochem Behav. 2011 Mar;98(1):150-4. [Content Brief]
- [3]. Kim JS, et, al. Safety and Efficacy of Otaplimastat in Patients with Acute Ischemic Stroke Requiring tPA (SAFE-TPA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study. Ann Neurol. 2020 Feb;87(2):233-245. [Content Brief]
